Ensuring Compliance: Regulatory Must-Knows For Selling Gel Polish In The Us/Eu

Compliance isn’t cute. It’s a boring, paperwork-heavy, chemistry-adjacent discipline where your “brand story” stops mattering the second a regulator asks for your safety file, your batch traceability, and proof that you didn’t sell a consumer product that secretly belongs in a professional-only channel (or worse, contains a prohibited sensitizer). Sound harsh? Good. That’s the point.

I keep seeing the same fantasy: “If our gel looks premium and the label has the right vibe, we’re good.” No. You’re not. Not in the US. Not in the EU. And if you’re selling cross-border, your risk stacks fast.

So let’s talk gel polish regulations US EU the way people in the industry talk when the doors are closed and someone’s about to get blamed.

The hard truth: the EU is a documentation regime, the US is turning into one

The EU has been this way for years: you don’t “launch” a cosmetic product until you can prove it’s safe, traceable, and correctly notified. The CPNP isn’t a “nice-to-have.” It’s a gate. The European Commission describes the Cosmetic Products Notification Portal (CPNP) as the notification system built for Regulation (EC) No 1223/2009—and once it’s notified there, you don’t do extra national notifications. (single-market-economy.ec.europa.eu)

The US used to feel looser. It’s tightening. MoCRA changed the tone. FDA literally reminded industry in 2024 to comply with new facility registration and product listing requirements “by July 1, 2024,” tied to its compliance policy. (U.S. Food and Drug Administration)

Different systems. Same direction. More receipts. Less guessing.

And here’s the part many brands hate hearing: if you’re not set up like a regulated manufacturer, you’re basically borrowing time.

Why “one label for US + EU” is where bad launches go to die

Yes, you can harmonize. But if you pretend the rules are identical, you’ll miss the stuff that gets you flagged.

In the EU, the Responsible Person concept forces accountability. In the US, the “responsible person” language shows up in MoCRA too, but enforcement patterns and expectations still differ.

What I see in real audits:

• Brands over-focus on front label marketing and under-build back-end evidence
• They treat “restricted ingredients in gel polish” like a rumor list
• They rely on a supplier COA like it’s a force field It isn’t.

If you want fewer sleepless nights, build your compliance like a manufacturing system: stable inputs, controlled process, documented outputs.

That’s also why I always tell brands to wire compliance into product development early. If you’re still deciding whether you’ll go HEMA-free at the end, you’re doing it backwards. If you need a starting point, browse a supplier’s line that already signals risk-aware formulation choices—like this HEMA/TPO-free gel polish assortment—then work backward into your safety and labeling plan. (Example SKU approach: HEMA/TPO-free color range for salon use.) https://bestgelpolish.com/oem-hema-tpo-free-84-color-uv-gel-nail-polish-for-salon-use/

The EU warning light that should scare you (it’s data, not drama)

If you think regulators don’t care about cosmetics, look at the numbers.

In the EU’s Safety Gate annual reporting for 2024, 4,137 alerts were validated. Cosmetics took the biggest share in 2024 at 36% of alerts (up from 32% in 2023).

That’s not a small signal. That’s market surveillance saying, “We’re watching you.”

Even worse for lazy compliance: the same report notes that 97% of cosmetics alerts with a chemical risk were tied to products reported to contain BMHCA (a fragrance ingredient banned from the EU market since March 2022).

Read that again. A banned ingredient. Still showing up. In huge volume.

If you sell gel polish in the EU, you’re operating in a system that assumes you can be wrong—and then checks.

US reality check: FDA doesn’t “approve” your gel polish, but it can still ruin your month

A lot of people keep repeating “FDA doesn’t approve cosmetics” like it’s a free pass. It’s not. It just means the control mechanism is different.

FDA’s own nail products page lays out a blunt history lesson: after injury complaints in the 1970s, FDA used court actions and recalls to remove products containing 100% methyl methacrylate (MMA) monomer from the market. (U.S. Food and Drug Administration)

That’s the actual posture: they may not pre-clear your product, but they will move when harm shows up or the product looks misbranded/adulterated.

Now add MoCRA. More obligations. More traceability. More reporting.

So when people ask me, “Do we really need to take FDA gel polish regulations seriously?” I answer: you don’t need to be scared. You need to be organized.

What “compliance” means in practice (not as a buzzword)

This is where most brands choke: compliance isn’t one task. It’s a small operating system.

Here’s the version I’d trust if I were putting my name on the label:

• A controlled formula (with clear INCI naming and concentrations)
• Supplier qualification (raw material specs, impurity limits, trace contaminants)
• Batch records (who made it, when, lot coding, where it shipped)
• Stability + compatibility thinking (does the bottle, brush, wiper, pigment load behave over time?)
• A labeling file (not just artwork—claims logic and warning logic)
• A safety file you can hand over quickly without panicking

This is also why your vendor matters. If your manufacturer can’t show you how they run QA, you’re buying risk. Period. If you want to see what “we can document it” looks like, start from a quality assurance process that’s built for audit questions: https://bestgelpolish.com/quality-assurance/

US vs EU compliance, side-by-side

How to sell gel polish in the EU legally (what people don’t say out loud)

You don’t “sell in the EU.” You place on the EU market under a Responsible Person who can answer for the product.

What that means in real terms:

1. Your file must exist before the product ships
2. Your notification must be done before the product goes live
3. Your claims must match your evidence
4. Your ingredient choices must survive scrutiny (not just “trend compliance”)

I know brands that can design a label in a weekend. But they can’t produce a defensible product file in a week. That’s the gap. That’s where EU enforcement lives.

If you’re building your EU plan now, start by deciding what you’re actually selling: classic soak-off color gel, rubber base, BIAB, builder gel, top coat, and so on. Each category has different usage patterns, exposure assumptions, and claim risks. If you need a catalog map to keep your SKU scope clean, keep it simple and structured: https://bestgelpolish.com/gel-polish-catalog/

Labeling requirements US EU: the fast way to get it right

Here’s my practical approach: treat the label as the final output of a larger “truth system.”

• The formula drives the ingredient list
• The safety logic drives the warnings
• The business reality drives the responsible party info
• The market drives language + formatting rules

If your label says “non-toxic” but you can’t define what that means, you’re asking for problems. Same with “HEMA-free” if your supply chain can’t prove it batch by batch.

And yes, base/top products matter here too because they often contain different photoinitiator systems, viscosity modifiers, and monomers. If you’re scaling, you may want a controlled bulk option like HEMA-free/TPO-free base + top coat gel in bulk to reduce variability across markets. https://bestgelpolish.com/wholesale-hema-free-tpo-free-base-top-coat-gel-1kg-for-salons/

If you’re private label, you need to stop pretending the factory “owns” the risk

I’m going to say this bluntly: if your brand name is on the bottle, you own the headache.

A strong factory helps. A good OEM/ODM partner can reduce your mistake rate. But you still need your own checklist, your own release rules, and your own “no ship without documents” policy.

If you’re building that kind of program, start with a manufacturer relationship that’s used to supporting private label documentation workflows, not just shipping cartons. https://bestgelpolish.com/oem-odm-services/

FAQs

Do you need FDA approval to sell gel polish in the US?

Gel polish does not require FDA premarket approval because cosmetics generally aren’t approved before sale, but you must still ensure the product is not adulterated or misbranded and you must follow modern requirements like facility registration and product listing timelines tied to MoCRA and FDA compliance policy. (U.S. Food and Drug Administration) In plain terms: FDA may not “approve” it, but it can act fast when products cause harm, violate labeling rules, or trigger compliance failures.

What are gel polish regulations US EU in one sentence?

Gel polish regulations US EU means you’re meeting US FDA/MoCRA expectations for safe, properly labeled cosmetics while also meeting EU Regulation (EC) 1223/2009 obligations like Responsible Person accountability and CPNP notification before market placement, with strong documentation that survives inspection. (single-market-economy.ec.europa.eu) If you try to treat both markets like one checklist, you’ll miss something that matters.

What is CPNP notification for gel polish, and when do you do it?

CPNP notification is the EU’s centralized online notification step for cosmetic products under Regulation (EC) No 1223/2009, and it’s done before the product is placed on the EU market so authorities can access key product information without separate national filings. (single-market-economy.ec.europa.eu) Do it after your documentation is complete, not while you’re still guessing about the final formula or label.

Why do “banned substances in gel polish EU” keep showing up in enforcement?

“Banned substances in gel polish EU” keep showing up because market surveillance finds real-world products that don’t match the rules, especially in online and cross-border channels, and Safety Gate data shows cosmetics were a top alert category in 2024 with chemical-risk patterns that repeat at scale. The ugly part: some brands don’t test, don’t verify supplier changes, and don’t control reformulations.

What’s the biggest labeling mistake brands make in the US/EU?

The biggest labeling mistake is treating the label as design-only instead of evidence-only: brands add claims they can’t support, omit required warnings for realistic misuse, and fail to align the ingredient list and responsible party details with what’s actually in the bottle and who’s accountable. If your compliance file can’t explain every claim and every ingredient choice, your label is a liability.

How do you lower compliance risk when scaling SKUs across the US and EU?

Lowering compliance risk means standardizing formulas, controlling raw materials, maintaining batch traceability, and using repeatable QA release rules so every shipment can be defended with the same document set, not last-minute “we’ll find it” scrambling. That’s why serious brands centralize QA and documentation instead of letting each new color launch invent its own process.

conclusion

If you’re selling in both markets, don’t “hope” your way through compliance. Build it.

Start by reviewing your formula and documentation workflow with a team that can support private label launch requirements, QA evidence, and repeatable production controls. You can explore our catalog and capabilities here: https://bestgelpolish.com/gel-polish-catalog/ and https://bestgelpolish.com/quality-assurance/ When you’re ready to map your US/EU plan to your actual SKUs, talk to us directly: https://bestgelpolish.com/contact/